September 16th 2024
New data from ESMO 2024 support an initial dose of Radium223 prior to chemotherapy among patients with mCRPC.
FDA grants priority review to metastatic PCa agent
February 19th 2013The FDA has granted priority review to the new drug application filed for radium-223 dichloride, an investigational compound under review for the treatment of patients with castration-resistant prostate cancer who have bone metastases.